0001564590-20-046256.txt : 20201013 0001564590-20-046256.hdr.sgml : 20201013 20201013083020 ACCESSION NUMBER: 0001564590-20-046256 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20201013 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20201013 DATE AS OF CHANGE: 20201013 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HERON THERAPEUTICS, INC. /DE/ CENTRAL INDEX KEY: 0000818033 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 942875566 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33221 FILM NUMBER: 201234723 BUSINESS ADDRESS: STREET 1: 4242 CAMPUS POINT COURT, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8582514400 MAIL ADDRESS: STREET 1: 4242 CAMPUS POINT COURT, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: AP PHARMA INC /DE/ DATE OF NAME CHANGE: 20010511 FORMER COMPANY: FORMER CONFORMED NAME: ADVANCED POLYMER SYSTEMS INC /DE/ DATE OF NAME CHANGE: 19920703 8-K 1 hrtx-8k_20201013.htm 8-K hrtx-8k_20201013.htm
false 0000818033 0000818033 2020-10-13 2020-10-13

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 13, 2020

 

Heron Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

001-33221

 

94-2875566

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

4242 Campus Point Court, Suite 200, San Diego, CA

 

92121

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code (858) 251-4400

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.01 per share

 

HRTX

 

The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 13, 2020, Heron Therapeutics, Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) elected Barry Quart, Pharm.D., age 63, as Chairman of the Board, effective October 13, 2020. Dr. Quart has served as Chief Executive Officer and as a director of the Company since 2012, and as President and Chief Executive Officer of the Company since 2019. The Company also announced the resignation of Dr. Quart as President and the promotion of John Poyhonen, age 60, previously Executive Vice President, Chief Commercial Officer, to the role of President and Chief Commercial Officer, each effective October 13, 2020. Dr. Quart will continue in his role as Chief Executive Officer. Mr. Poyhonen served as a director of Heron from 2014 to August 2020 and was appointed Executive Vice President, Chief Commercial Officer in 2019. In connection with his promotion, Mr. Poyhonen was granted an option to purchase a total of up to 50,000 shares of the Company’s common stock at an exercise price equal to the closing price of the Company’s common stock on October 13, 2020, the date of grant (the “Poyhonen Stock Option”). The Poyhonen Stock Option will vest and become exercisable monthly over the next four years. The Poyhonen Stock Option has a ten year term.  

In connection with Dr. Quart’s election as Chairman of the Board, the independent directors of the Board appointed Craig Johnson to the role of Lead Independent Director, effective October 13, 2020. Mr. Johnson, age 58, has served as a director of the Company since 2014.

The Company also announced the promotion of David Szekeres, age 47, previously Senior Vice President, Chief Legal, Business and Administrative Officer, to the role of Executive Vice President, Chief Operating Officer, effective October 13, 2020. Mr. Szekeres joined Heron as Senior Vice President, General Counsel, Business Development and Corporate Secretary in 2016 and was promoted to Chief Legal, Business and Administrative Officer in 2019. In connection with his promotion, Mr. Szekeres’ annual base salary will be increased to $480,000. In addition, Mr. Szekeres was granted an option to purchase a total of up to 36,000 shares of the Company’s common stock at an exercise price equal to the closing price of the Company’s common stock on October 13, 2020, the date of grant (the “Szekeres Stock Option”). The Szekeres Stock Option will vest and become exercisable monthly over the next four years. The Szekeres Stock Option has a ten year term.

Additionally, the Company announced the retirement of Robert Hoffman, age 54, effective on October 16, 2020, the Company’s Chief Financial Officer and Senior Vice President, Finance and the Company’s principal financial officer and accounting officer (as defined under applicable securities laws) since 2017. In connection with his retirement, the Board granted Mr. Hoffman (i) a cash severance equivalent to Mr. Hoffman’s annual base salary; (ii) his current 100% target bonus (equivalent to 40% of the annual base salary); (iii) one year of paid health insurance coverage; and (iv) the accelerated vesting of each stock option held by Mr. Hoffman, such that each award that would have otherwise vested as of October 16, 2021, shall become exercisable as of October 16, 2020, with the date to exercise such options expiring on April 14, 2021. Also, effective on October 13, 2020, the Company announced the promotion of Lisa Peraza, age 44, to the role of Vice President, Chief Accounting Officer and the Company’s principal financial officer and accounting officer (as defined under applicable securities laws). Ms. Peraza joined the Company in 2014 and has served as Vice President, Controller since 2019. In connection with her promotion, Ms. Peraza’s annual base salary will be increased to $330,000. In addition, Ms. Peraza was granted an option to purchase a total of up to 50,000 shares of the Company’s common stock at an exercise price equal to the closing price of the Company’s common stock on October 13, 2020, the date of grant (the “Peraza Stock Option”). The Peraza Stock Option will vest and become exercisable monthly over the next four years. The Peraza Stock Option has a ten year term.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

Heron Therapeutics, Inc.

 

 

 

 

Date: October 13, 2020

 

 

/s/ David Szekeres

 

 

 

David Szekeres

Executive Vice President, Chief Operating Officer

 

 EX-101.SCH 2 hrtx-20201013.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 hrtx-20201013_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 4 hrtx-20201013_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 hrtx-8k_20201013_htm.xml IDEA: XBRL DOCUMENT 0000818033 2020-10-13 2020-10-13 false 0000818033 8-K 2020-10-13 Heron Therapeutics, Inc. DE 001-33221 94-2875566 4242 Campus Point Court Suite 200 San Diego CA 92121 (858) 251-4400 false false false false Common Stock, par value $0.01 per share HRTX NASDAQ false XML 6 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information
Oct. 13, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 13, 2020
Entity Registrant Name Heron Therapeutics, Inc.
Entity Central Index Key 0000818033
Entity Emerging Growth Company false
Entity File Number 001-33221
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 94-2875566
Entity Address, Address Line One 4242 Campus Point Court
Entity Address, Address Line Two Suite 200
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code (858)
Local Phone Number 251-4400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol HRTX
Security Exchange Name NASDAQ
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.herontx.com/20201013/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports hrtx-8k_20201013.htm hrtx-20201013.xsd hrtx-20201013_lab.xml hrtx-20201013_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "hrtx-8k_20201013.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "hrtx-8k_20201013.htm" ] }, "labelLink": { "local": [ "hrtx-20201013_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "hrtx-20201013_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "hrtx-20201013.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "hrtx", "nsuri": "http://www.herontx.com/20201013", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "hrtx-8k_20201013.htm", "contextRef": "C_0000818033_20201013_20201013", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.herontx.com/20201013/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "hrtx-8k_20201013.htm", "contextRef": "C_0000818033_20201013_20201013", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.herontx.com/20201013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.herontx.com/20201013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.herontx.com/20201013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.herontx.com/20201013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.herontx.com/20201013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.herontx.com/20201013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.herontx.com/20201013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.herontx.com/20201013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.herontx.com/20201013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.herontx.com/20201013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.herontx.com/20201013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.herontx.com/20201013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.herontx.com/20201013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.herontx.com/20201013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.herontx.com/20201013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.herontx.com/20201013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.herontx.com/20201013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.herontx.com/20201013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "verboseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.herontx.com/20201013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.herontx.com/20201013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.herontx.com/20201013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.herontx.com/20201013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.herontx.com/20201013/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 13 0001564590-20-046256-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-20-046256-xbrl.zip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end